# Infacare Pharmaceutical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/infacare-pharmaceutical

- Industry: Pharmaceuticals
- Headquarters: US
- Website: www.infacare.com
- Total disclosed funding: $56M
- Latest round: Series C (Jun 23, 2015)
- Investors on record: 4

## About

Infacare Pharmaceutical Corp. is dedicated to developing innovative pharmaceutical solutions aimed at improving patient care in critical health areas, particularly for pediatric patients requiring specialized medical treatments.Infacare Pharmaceutical Corp. focuses on delivering pharmaceutical products with an emphasis on pediatric care. Founded in 2005 in the US, Infacare has undergone strategic developments to enhance its offerings. The company successfully raised USD 12.10 mn in Series C funding on June 23, 2015, with investments from Atlas Venture and Longitude Capital, contributing to a total amount raised of USD 12.10 mn and a current company valuation of USD 40.36 mn.Infacare Pharmaceutical Corp. provides a range of specialty pharmaceuticals designed for pediatric patients, focusing on critical healthcare areas. Their product offerings include formulations for pain management and other therapeutic needs, specifically tailored to meet the requirements of children and adolescents, ensuring safe and effective treatment options in various healthcare settings.Infacare Pharmaceutical Corp. generates revenue through direct sales of its specialty medications to healthcare providers, hospitals, and outpatient facilities. Revenue streams include contracts with healthcare institutions and partnerships with distributors, facilitating the availability of their critical care products across multiple channels, ensuring accessibility for pediatric patients in need of specialized care.Infacare Pharmaceutical Corp. aims to expand its market presence by developing new pediatric formulations, with anticipated launches planned in the upcoming years. The company targets geographic expansion into emerging markets in Asia and Europe by 2025. The recent Series C funding of USD 12.10 mn will be utilized to support product development and market entry initiatives, thereby enhancing their ability to provide targeted medical solutions for pediatric care.

## Funding rounds

- Series C, Jun 23, 2015, $12M — Atlas Venture, Longitude Capital
- Series C, Mar 20, 2013, $3.6M — Atlas Venture, HealthCare Ventures, Longitude Capital, FirstMark Capital
- Series B, Oct 8, 2008, $8M — Atlas Venture, HealthCare Ventures, Longitude Capital, FirstMark Capital
- Series B, Aug 28, 2008, $20M — Atlas Venture, HealthCare Ventures, Longitude Capital, FirstMark Capital
- Series A, Mar 10, 2006, $12M — Atlas Venture, FirstMark Capital

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A, Series B, Series C
- FirstMark Capital (https://capitalatlas.ai/funds/firstmark-capital) — Series A, Series B, Series C
- HealthCare Ventures — Series B, Series C
- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series B, Series C